RCS - Cambridge Cognition - Capital Markets Day

Cambridge Cognition HoldingsAnnouncement

31/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230531:nRSe0796Ba&default-theme=true

RNS Number : 0796B  Cambridge Cognition Holdings PLC  31 May 2023

31 May 2023

 

Cambridge Cognition Holdings Plc

("Cambridge Cognition" or the "Company")

 

Capital Markets Day

 

Cambridge Cognition Holdings plc ("the Company"), which develops and markets
digital solutions to assess brain health, is pleased to announce that it will
be hosting a Capital Markets Day on 14 June 2023 at 14:00 in the Great Room at
Central Court, 25 Southampton Buildings, London WC2A 1AL.

The event will feature a series of presentations from Cambridge Cognition's
management and senior leadership team focussing on the latest developments in
the Company's product and technology portfolios.

To express interest in attending the event please email:
cog@investor-focus.co.uk (mailto:cog@investor-focus.co.uk)

No material new information or update on current trading will be disclosed at
the event.

 

Enquiries:

 Cambridge Cognition Holdings Plc             Tel: 012 2381 0700

 Matthew Stork, Chief Executive Officer       press@camcog.com (mailto:press@camcog.com)

 Stephen Symonds, Chief Financial Officer
 Panmure Gordon (UK) Limited                  Tel: 020 7886 2500

(NOMAD and Joint Broker)

                                            (Corporate Advisory)
 Freddy Crossley / Emma Earl / Mark Rogers

                                            (Corporate Broking)
 Rupert Dearden
 Dowgate Capital Limited (Joint Broker)       Tel: 020 3903 7715

 David Poutney / James Serjeant
 IFC Advisory Limited (Financial PR and IR)   Tel: 020 3934 6630

 Tim Metcalfe / Graham Herring / Zach Cohen   cog@investor-focus.co.uk (mailto:cog@investor-focus.co.uk)

 

About Cambridge Cognition

Cambridge Cognition is a technology company developing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com
(http://www.cambridgecognition.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAWPUCCAUPWGQU